Impacts of ERCC1, DPD, and EGFR on gastric cancer patients
Author Information
Author(s): Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima T E, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K
Primary Institution: National Cancer Center Hospital
Hypothesis
The clinical outcomes of chemotherapy in patients with advanced gastric cancer are related to the pretreatment intratumour mRNA levels of enzymes participating in critical pathways of drug resistance.
Conclusion
High DPD and ERCC1 gene expression levels are significant predictors of poor survival in patients with advanced gastric cancer.
Supporting Evidence
- Low MTHFR expression correlated with a higher response rate in patients receiving S-1 monotherapy.
- Low ERCC1 expression correlated with a higher response rate in patients receiving cisplatin-based regimens.
- High ERCC1 and DPD expression were significant predictors of poor survival.
- Low EGFR expression was associated with better survival outcomes.
Takeaway
This study found that certain genes can help predict how well patients with advanced stomach cancer will respond to treatment.
Methodology
The study evaluated mRNA levels of biomarkers in gastric cancer specimens from patients who received first-line chemotherapy using laser-captured microdissection and real-time RT–PCR.
Limitations
The relatively small sample size precludes drawing firm conclusions, and candidate biomarkers must be validated in prospective studies.
Participant Demographics
The study included 140 patients, with 77% men and a median age of 65 years.
Statistical Information
P-Value
P=0.006 for MTHFR; P=0.008 for ERCC1
Confidence Interval
95% CI: 1.55–3.67 for ERCC1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website